<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666224</url>
  </required_header>
  <id_info>
    <org_study_id>GA 9010</org_study_id>
    <nct_id>NCT00666224</nct_id>
  </id_info>
  <brief_title>Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome</brief_title>
  <acronym>PreCISe</acronym>
  <official_title>A Multinational, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Early Glatiramer Acetate Treatment in Delaying the Conversion to Clinically Definite Multiple Sclerosis (CDMS) of Subjects Presenting With Clinically Isolated Syndrome (CIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the effect of treatment with glatiramer acetate (GA)
      compared to placebo on the time to conversion to CDMS, as determined by Poser criteria (the
      occurrence of the second clinical attack) during the double-blind period. The secondary
      objective is to assess, within the time frame of the up to 3-year double-blind,
      placebo-controlled study period, the effect of GA on clinical and Magnetic Resonance Imaging
      (MRI) parameters. The long-term objectives of the study (exploratory in nature) are to
      assess, within the time frame of 5 years, the neuroprotective effect of early versus delayed
      treatment with GA as reflected by clinical and MRI parameters measuring the accumulated
      irreversible brain tissue damage.

      A pre-planned interim analysis was performed on all efficacy and safety data accumulated in
      the database up to October 14, 2007, i.e. when 81% of exposure to treatment in the
      double-blind, placebo-controlled period had been collected. Upon review of the interim
      analysis results, the Data Monitoring Committee (DMC) recommended that the double-blind
      portion of the study be stopped and that subjects be switched to the 2-year Open-label
      period, during which time they would have the option of receiving GA therapy. The sponsor
      (Teva) adopted the DMC recommendations and took the necessary action towards its
      implementation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Data from interim analysis with database lock on October 14, 2007. The time from randomization to conversion to CDMS as determined by the occurrence of a second clinical attack during the double-blind period. Poser criteria are: Two relapses and clinical evidence of two separate lesions; clinical evidence of one lesion and paraclinical evidence of another separate lesion. The two relapses must involve different parts of Central Nervous System and must be separated by a period of at least one month. Lesions are determined by Magnetic Resonance Imaging (MRI).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Twenty-fifth Percentile (25%) Kaplan-Meier Estimates for Time From Randomization to Conversion to Clinically Definite Multiple Sclerosis (CDMS) During the Double-blind Period</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Data from interim analysis with database lock on October 14, 2007. Due to the number of participants in the glatiramer acetate group that converted to CDMS (see outcome #6), the 25th percentile was considered when running the Kaplan-Meier estimate for time to conversion to CDMS. Conversion to CDMS is determined by the occurrence of the second clinical attack.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of New T2 Brain Lesions Observed at the Last Observed Value (LOV) in the Double-blind Period</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Data from interim analysis with database lock on October 14, 2007. T2 lesions are brain lesions that show on magnetic resonance imaging (MRI) and are associated with multiple sclerosis. This outcome measures the number of new lesions at the last observed value. Last Observed Value (LOV) is defined as the last post baseline measurement taken on study drug but no more than 30 days after study drug cessation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Last Observed Value (LOV) in T2 Brain Lesion Volume in the Double-blind Period</measure>
    <time_frame>Day 0 (baseline), up to 3 years</time_frame>
    <description>Data from interim analysis with database lock on October 14, 2007. The difference in T2 brain lesion volume as observed in MRIs from baseline to the last observed value. Last Observed Value (LOV) is defined as the last post baseline measurement taken on study drug but no more than 30 days after study drug cessation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Brain Volume From Baseline to the Last Observed Value (LOV) During the Double-blind Period Using the Structural Image Evaluation of Normalized Atrophy (SIENA) Technique</measure>
    <time_frame>Day 0 (baseline), up to 3 years</time_frame>
    <description>Data from interim analysis with database lock on October 14, 2007. Brain volume was measured annually by magnetic resonance imaging (MRI) during the Double-blind period. Brain atrophy was measured by comparing the change in brain volume from baseline to the Last Observed Value (LOV). LOV is defined as the last post baseline measurement taken on study drug but no more than 30 days after study drug cessation. SIENA is a fully automated method of analyzing longitudinal brain change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Converted to Clinically Definite Multiple Sclerosis (CDMS) During the Double-blind Period</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Data from interim analysis with database lock on October 14, 2007. Conversion to CDMS as determined by the occurrence of a second clinical attack during the double-blind period. Poser criteria are: Two relapses and clinical evidence of two separate lesions; clinical evidence of one lesion and paraclinical evidence of another separate lesion. The two relapses must involve different parts of Central Nervous System and must be separated by a period of at least one month. Lesions are determined by Magnetic Resonance Imaging (MRI).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">481</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Glatiramer acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glatiramer acetate 20 mg once daily by subcutaneous injection is administered in both the double-blind and open label periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (DB) to GA (OL)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching glatiramer acetate once daily by subcutaneous injection during the double-blind period (DB). Glatiramer acetate (GA) 20 mg once daily by subcutaneous injection during the open-label period (OL).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glatiramer Acetate (DB)</intervention_name>
    <description>Double blind period (DB): glatiramer acetate (GA) by subcutaneous injection, 20mg, once daily, for up to 36 months or until conversion to clinically definite multiple sclerosis (CDMS).</description>
    <arm_group_label>Glatiramer acetate</arm_group_label>
    <other_name>Copaxone®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS</description>
    <arm_group_label>Placebo (DB) to GA (OL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glatiramer Acetate (OL)</intervention_name>
    <description>Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.</description>
    <arm_group_label>Glatiramer acetate</arm_group_label>
    <arm_group_label>Placebo (DB) to GA (OL)</arm_group_label>
    <other_name>Copaxone®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject must have undergone a single clinical attack.

          2. The subject must have a unifocal clinical presentation.

          3. The subject should be enrolled within the period of 90 days after onset of a single
             unifocal clinical attack (index attack).

          4. There must be 2 or more cerebral lesions highly suspicious of multiple sclerosis (MS)
             on the screening Magnetic Resonance Imaging (MRI), measuring 6mm or more in diameter.

          5. Subjects must be between the ages of 18 and 45 years inclusive.

          6. Subjects must not have taken corticosteroids within the 30 days prior to the MRI at
             the baseline visit.

          7. Subjects may be male or female. Women of child-bearing potential must practice a
             medically acceptable method of birth control. Acceptable methods include oral
             contraceptive, contraceptive patch, long-acting injectable contraceptive, or
             double-barrier method (condom or intrauterine device with spermicide).

          8. The subjects must be willing and able to give written informed consent, prior to
             entering the study.

        Exclusion Criteria:

          1. Multifocal clinical presentation.

          2. Diseases other than MS responsible for the clinical/MRI presentation. The following
             laboratory tests must be part of the subject's medical history for differential
             diagnosis of clinically isolated syndrome (CIS): erythrocyte sedimentation rate (ESR),
             antinuclear antibody (ANA), complement (C3, C4) and anticardiolipin IgG - IgM. In the
             event that the results of these tests are inconclusive, the following additional tests
             may be requested by the Eligibility Evaluation Committee: syphilis screening, vitamin
             B12 and folic acid. In the case of spinal cord CIS presentation, a spinal cord MRI is
             required for confirmation of diagnosis in the medical history of the subject.

          3. Use of experimental or investigational drugs, including IV immunoglobulin, and/or
             participation in an investigational drug study within 6 months prior to study entry.

          4. Use of interferon agents within 6 months prior to the screening visit.

          5. Chronic corticosteroid treatment (more than 30 consecutive days) in the 6 months prior
             to study entry.

          6. Pregnancy or breast feeding.

          7. Subjects who experience a relapse between the screening (month -1) and baseline (month
             0) visits.

          8. Life-threatening or other clinically significant disease.

          9. A medical or psychiatric condition that affects the subject's ability to give informed
             consent, or to complete the study, or if the subject is considered by the treating
             neurologist/physician to be, for any other reason, an unsuitable candidate for this
             study.

         10. A known history of sensitivity to mannitol.

         11. A known history of sensitivity to gadolinium.

         12. Inability to successfully undergo MRI scanning.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 31;374(9700):1503-11. doi: 10.1016/S0140-6736(09)61259-9. Epub 2009 Oct 6. Erratum in: Lancet. 2010 Apr 24;375(9724):1436.</citation>
    <PMID>19815268</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <results_first_submitted>May 3, 2012</results_first_submitted>
  <results_first_submitted_qc>May 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 13, 2012</results_first_posted>
  <last_update_submitted>June 19, 2012</last_update_submitted>
  <last_update_submitted_qc>June 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinically Definite Multiple Sclerosis</keyword>
  <keyword>Clinically Isolated Syndrome</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glatiramer Acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A clinically isolated syndrome (CIS) is a first neurological episode, lasting at least 24 hours, caused by inflammation/demyelination in one or more sites in the central nervous system (CNS.) Subjects were enrolled within 90 days of the event and randomized up to 32 days following screening.</recruitment_details>
      <pre_assignment_details>Six-hundred and nineteen (619) subjects were screened for this study; 138 subjects were screening failures, including one subject, randomized in error. This subject, who had a relapse between screening visit and baseline, never received any treatment, and is considered a screening failure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Glatiramer Acetate</title>
          <description>Glatiramer acetate (GA) 20 mg once daily by subcutaneous injection during the double-blind period. Following a pre-planned interim analysis, the Data Monitoring Committee (DMC) recommended that the double blind period be closed and participants moved into the Open Label (OL) period. Participants in this treatment arm continued taking glatiramer acetate 20 mg once daily by subcutaneous injection during the open-label (OL) period.</description>
        </group>
        <group group_id="P2">
          <title>Placebo (DB) to GA (OL)</title>
          <description>Placebo matching glatiramer acetate given once daily by subcutaneous injection during the double-blind period (DB). Following a pre-planned interim analysis, the Data Monitoring Committee (DMC) recommended that the double blind period be closed and participants moved into the Open Label (OL) period. Glatiramer acetate (GA) given 20 mg once daily by subcutaneous injection during the open-label period (OL).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="243"/>
                <participants group_id="P2" count="238"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="198">78 completed 3 years treatment, 66 converted to CDMS, 54 switched to OL as per DMC</participants>
                <participants group_id="P2" count="211">55 completed 3 years treatment, 109 converted to CDMS, 47 switched to OL as per DMC</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Undefined/Unknown</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="198">454 participants took at least one dose of GA including 45 who didn't continue into the OL.</participants>
                <participants group_id="P2" count="211"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Undefined/Unknown</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glatiramer Acetate (Double-blind Period)</title>
          <description>Glatiramer acetate 20 mg once daily by subcutaneous injection during the double-blind period.</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Double-blind Period)</title>
          <description>Placebo matching GA once daily by subcutaneous injection during the double-blind period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="243"/>
            <count group_id="B2" value="238"/>
            <count group_id="B3" value="481"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" spread="6.9"/>
                    <measurement group_id="B2" value="30.8" spread="7.0"/>
                    <measurement group_id="B3" value="31.2" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian / Oriental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="229"/>
                    <measurement group_id="B3" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (not specified)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants Who Used Corticosteroids for Initial Attack</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Used corticosteroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not use corticosteroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion</title>
        <description>Data from interim analysis with database lock on October 14, 2007. The time from randomization to conversion to CDMS as determined by the occurrence of a second clinical attack during the double-blind period. Poser criteria are: Two relapses and clinical evidence of two separate lesions; clinical evidence of one lesion and paraclinical evidence of another separate lesion. The two relapses must involve different parts of Central Nervous System and must be separated by a period of at least one month. Lesions are determined by Magnetic Resonance Imaging (MRI).</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intent-to-Treat (ITT) analysis set. The ITT consists of all participants who have been randomized and received at least one dose of glatiramer acetate or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate (Double-blind Period)</title>
            <description>Glatiramer acetate 20 mg once daily by subcutaneous injection during the double-blind period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-blind Period)</title>
            <description>Placebo matching GA once daily by subcutaneous injection during the double-blind period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion</title>
          <description>Data from interim analysis with database lock on October 14, 2007. The time from randomization to conversion to CDMS as determined by the occurrence of a second clinical attack during the double-blind period. Poser criteria are: Two relapses and clinical evidence of two separate lesions; clinical evidence of one lesion and paraclinical evidence of another separate lesion. The two relapses must involve different parts of Central Nervous System and must be separated by a period of at least one month. Lesions are determined by Magnetic Resonance Imaging (MRI).</description>
          <population>Intent-to-Treat (ITT) analysis set. The ITT consists of all participants who have been randomized and received at least one dose of glatiramer acetate or placebo.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="657.85" spread="349.3"/>
                    <measurement group_id="O2" value="590.54" spread="340.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>Type of unifocal presentation at baseline, past corticosteroid treatment (Yes/No) for the initial attack prior to randomization, and center effects as covariates.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New T2 Brain Lesions Observed at the Last Observed Value (LOV) in the Double-blind Period</title>
        <description>Data from interim analysis with database lock on October 14, 2007. T2 lesions are brain lesions that show on magnetic resonance imaging (MRI) and are associated with multiple sclerosis. This outcome measures the number of new lesions at the last observed value. Last Observed Value (LOV) is defined as the last post baseline measurement taken on study drug but no more than 30 days after study drug cessation.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intent-to-Treat (ITT) analysis set. The ITT consists of all participants who have been randomized and received at least one dose of glatiramer acetate or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate (Double-blind Period)</title>
            <description>Glatiramer acetate 20 mg once daily by subcutaneous injection during the double-blind period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-blind Period)</title>
            <description>Placebo matching GA once daily by subcutaneous injection during the double-blind period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New T2 Brain Lesions Observed at the Last Observed Value (LOV) in the Double-blind Period</title>
          <description>Data from interim analysis with database lock on October 14, 2007. T2 lesions are brain lesions that show on magnetic resonance imaging (MRI) and are associated with multiple sclerosis. This outcome measures the number of new lesions at the last observed value. Last Observed Value (LOV) is defined as the last post baseline measurement taken on study drug but no more than 30 days after study drug cessation.</description>
          <population>Intent-to-Treat (ITT) analysis set. The ITT consists of all participants who have been randomized and received at least one dose of glatiramer acetate or placebo.</population>
          <units>new T2 lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.7"/>
                    <measurement group_id="O2" value="1.8" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Quasi-Likelihood NB* Regression</method>
            <method_desc>*NB = Negative Binomial
Center and baseline number of enhancing lesions as covariates.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Last Observed Value (LOV) in T2 Brain Lesion Volume in the Double-blind Period</title>
        <description>Data from interim analysis with database lock on October 14, 2007. The difference in T2 brain lesion volume as observed in MRIs from baseline to the last observed value. Last Observed Value (LOV) is defined as the last post baseline measurement taken on study drug but no more than 30 days after study drug cessation.</description>
        <time_frame>Day 0 (baseline), up to 3 years</time_frame>
        <population>Intent to treat population for which data at both timepoints are available</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate (Double-blind Period)</title>
            <description>Glatiramer acetate 20 mg once daily by subcutaneous injection during the double-blind period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-blind Period)</title>
            <description>Placebo matching GA once daily by subcutaneous injection during the double-blind period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Last Observed Value (LOV) in T2 Brain Lesion Volume in the Double-blind Period</title>
          <description>Data from interim analysis with database lock on October 14, 2007. The difference in T2 brain lesion volume as observed in MRIs from baseline to the last observed value. Last Observed Value (LOV) is defined as the last post baseline measurement taken on study drug but no more than 30 days after study drug cessation.</description>
          <population>Intent to treat population for which data at both timepoints are available</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="2.6"/>
                    <measurement group_id="O2" value="2.6" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>ANCOVA</method>
            <method_desc>Used log-transformed measurements comparing the adjusted geometric means of T2 volume. Center and baseline T2 volume used as covariates.</method_desc>
            <param_type>Geometric means ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Brain Volume From Baseline to the Last Observed Value (LOV) During the Double-blind Period Using the Structural Image Evaluation of Normalized Atrophy (SIENA) Technique</title>
        <description>Data from interim analysis with database lock on October 14, 2007. Brain volume was measured annually by magnetic resonance imaging (MRI) during the Double-blind period. Brain atrophy was measured by comparing the change in brain volume from baseline to the Last Observed Value (LOV). LOV is defined as the last post baseline measurement taken on study drug but no more than 30 days after study drug cessation. SIENA is a fully automated method of analyzing longitudinal brain change.</description>
        <time_frame>Day 0 (baseline), up to 3 years</time_frame>
        <population>Intent to treat population of participants with both baseline and last observed values.</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate (Double-blind Period)</title>
            <description>Glatiramer acetate 20 mg once daily by subcutaneous injection during the double-blind period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-blind Period)</title>
            <description>Placebo matching GA once daily by subcutaneous injection during the double-blind period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Brain Volume From Baseline to the Last Observed Value (LOV) During the Double-blind Period Using the Structural Image Evaluation of Normalized Atrophy (SIENA) Technique</title>
          <description>Data from interim analysis with database lock on October 14, 2007. Brain volume was measured annually by magnetic resonance imaging (MRI) during the Double-blind period. Brain atrophy was measured by comparing the change in brain volume from baseline to the Last Observed Value (LOV). LOV is defined as the last post baseline measurement taken on study drug but no more than 30 days after study drug cessation. SIENA is a fully automated method of analyzing longitudinal brain change.</description>
          <population>Intent to treat population of participants with both baseline and last observed values.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.6"/>
                    <measurement group_id="O2" value="-0.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Twenty-fifth Percentile (25%) Kaplan-Meier Estimates for Time From Randomization to Conversion to Clinically Definite Multiple Sclerosis (CDMS) During the Double-blind Period</title>
        <description>Data from interim analysis with database lock on October 14, 2007. Due to the number of participants in the glatiramer acetate group that converted to CDMS (see outcome #6), the 25th percentile was considered when running the Kaplan-Meier estimate for time to conversion to CDMS. Conversion to CDMS is determined by the occurrence of the second clinical attack.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intent-to-Treat (ITT) analysis set. The ITT consists of all participants who have been randomized and received at least one dose of glatiramer acetate or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate (Double-blind Period)</title>
            <description>Glatiramer acetate 20 mg once daily by subcutaneous injection during the double-blind period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-blind Period)</title>
            <description>Placebo matching GA once daily by subcutaneous injection during the double-blind period.</description>
          </group>
        </group_list>
        <measure>
          <title>Twenty-fifth Percentile (25%) Kaplan-Meier Estimates for Time From Randomization to Conversion to Clinically Definite Multiple Sclerosis (CDMS) During the Double-blind Period</title>
          <description>Data from interim analysis with database lock on October 14, 2007. Due to the number of participants in the glatiramer acetate group that converted to CDMS (see outcome #6), the 25th percentile was considered when running the Kaplan-Meier estimate for time to conversion to CDMS. Conversion to CDMS is determined by the occurrence of the second clinical attack.</description>
          <population>Intent-to-Treat (ITT) analysis set. The ITT consists of all participants who have been randomized and received at least one dose of glatiramer acetate or placebo.</population>
          <units>days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="722" lower_limit="505">Not able to be estimated due to small numbers of participants converting to CDMS</measurement>
                    <measurement group_id="O2" value="336" lower_limit="260" upper_limit="456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Converted to Clinically Definite Multiple Sclerosis (CDMS) During the Double-blind Period</title>
        <description>Data from interim analysis with database lock on October 14, 2007. Conversion to CDMS as determined by the occurrence of a second clinical attack during the double-blind period. Poser criteria are: Two relapses and clinical evidence of two separate lesions; clinical evidence of one lesion and paraclinical evidence of another separate lesion. The two relapses must involve different parts of Central Nervous System and must be separated by a period of at least one month. Lesions are determined by Magnetic Resonance Imaging (MRI).</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intent-to-Treat (ITT) analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate (Double-blind Period)</title>
            <description>Glatiramer acetate 20 mg once daily by subcutaneous injection during the double-blind period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-blind Period)</title>
            <description>Placebo matching GA once daily by subcutaneous injection during the double-blind period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Converted to Clinically Definite Multiple Sclerosis (CDMS) During the Double-blind Period</title>
          <description>Data from interim analysis with database lock on October 14, 2007. Conversion to CDMS as determined by the occurrence of a second clinical attack during the double-blind period. Poser criteria are: Two relapses and clinical evidence of two separate lesions; clinical evidence of one lesion and paraclinical evidence of another separate lesion. The two relapses must involve different parts of Central Nervous System and must be separated by a period of at least one month. Lesions are determined by Magnetic Resonance Imaging (MRI).</description>
          <population>Intent-to-Treat (ITT) analysis set.</population>
          <units>percentage of total participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7"/>
                    <measurement group_id="O2" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Type of unifocal presentation, past corticosteroid treatment (Yes/No) for the initial attack prior to randomization and center effects as covariates.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The double-blind period was up to three years. The entire study included the double-blind period (up to three years) and the open-label period (up to an additional two years).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Double-blind Period)</title>
          <description>Placebo matching GA once daily by subcutaneous injection during the double-blind period.</description>
        </group>
        <group group_id="E2">
          <title>Glatiramer Acetate (Double-blind Period)</title>
          <description>Glatiramer acetate 20 mg once daily by subcutaneous injection during the double-blind period. This subset of the GA treatment experience allows for comparison to the Placebo Double-blind Period data.</description>
        </group>
        <group group_id="E3">
          <title>Glatiramer Acetate (Entire Study)</title>
          <description>Glatiramer acetate (GA) 20 mg once daily by subcutaneous injection. GA adverse experiences from both the double-blind and open-label periods are combined in this column.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Multiple drug overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Visual field tests abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Cluster headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Intracranial venous sinus thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Imminent abortion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Anal fissure excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Appendicectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Breast reconstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Cholesteatoma removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Endometrial ablation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Haemorrhoid operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Lipoma excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Nail operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Resection of rectum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Skin neoplasm excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="191" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="352" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="454"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="454"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Should the investigator wish to publish the results of this study, he/she agrees to provide Teva with a manuscript for review 60 days prior to submission for publication. Teva retains the right to delete confidential information and to object to suggest publication and/or its timing (at the Company's sole discretion).
If Teva chooses to publish this study a copy will be provided to the investigator at least 30 days prior to the expected date of submission to the intended publisher.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yossi Gilgun, PhD, Global Clinical Leader</name_or_title>
      <organization>Teva Pharmaceutical Industries, Ltd.</organization>
      <phone>972-9-863-1491</phone>
      <email>yossi.gilgun@teva.co.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

